MEDICURE GETS U.S. PATENT NOTICE OF ALLOWANCE FOR THERAPEUDICS.Medicure Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :MPH), Winnipeg, Manitoba, a cardiovascular company, has received a Notice of Allowance from the U.S. Patent Office for a composition of matter patent covering several of the company's newly discovered therapeutics for use in treatment of several cardiovascular diseases, including thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. disorders and blood coagulation. Thrombosis, which involves the formation of clots in the blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. , is the major cause of cardiovascular and cerebrovascular disease cerebrovascular disease Neurology Any vascular disease affecting cerebral arteries–eg ASHD, diabetic vasculopathy, HTN, which may cause a CVA or TIA with neurologic sequelae–speech, vision, movement of variable duration. . The company's anti-thrombotic program addresses the unmet need in the prevention of arterial thrombosis (angioplasty, unstable angina, coronary arterial bypass graft, acute myocardial infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· and stroke). The global thrombosis market is estimated at over $7.5 billion and is expected to continue to grow rapidly. Medicure has focused its anti-thrombotic program on the design of novel structures that inhibit platelet aggregation, which is one of the causes of clot formation in the blood vessels, as well as Factor Xa inhibition (the coagulation factor). This unique multi-targeted approach will have a broader therapeutic profile. "This patent, when issued, together with previously issued patents, further highlights the strong intellectual property position of our drug discovery program," stated Albert D. Friesen, PhD, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "We are extremely pleased with the additional scope of protection that this patent will provide us with in the area of anti-thrombotics. Pre-clinical studies have already confirmed the potential of these therapeutic candidates." About Medicure Inc. Medicure Inc. is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine including the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. For more information, call 888-435-2220 or visit http://www.medicureinc.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion